Skip to main content
SpringerLink
Log in

Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain

  • Research Letter
  • Published:
Applied Health Economics and Health Policy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the MONET Trial using UK antiretroviral drug prices. Appl Health Econ Health Policy 2011; 9(4): 217–23

    Article  PubMed  Google Scholar 

  2. Arribas J, Clumeck N, Nelson M, et al. The MONET trial: week 144 analysis of efficacy of darunavir/ritonavir mono-therapy versus DRV/r+2 NRTIs, for patients with HIV RNA <50 copies/mL at baseline [abstract no. MOPE215]. 6th IAS Conference on HIV pathogenesis, treatment and prevention; 2011 Jul 17-20; Rome

  3. Ministerio de Sanidad y Consumo. Plan Multisectorial frente la infección por VIH y el SIDA: España 2008–2012 [online]. Available from URL: http://www.msc.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/PMS200812.pdf [Accessed 2011 Dec 15]

  4. Thompson M, Aberg J, Cahn P, et al. Antiretroviral treatment of adult HIV-1 infection: 2010 recommendations of the International AIDS Society USA panel. JAMA 2010; 304(3): 321–33

    Article  PubMed  CAS  Google Scholar 

  5. European AIDS Clinical Society (EACS). Guidelines for the clinical management of HIV infected adults in Europe [online]. Available from URL: http://www.europeanaid-sclinicalsociety.org/index.php?option=com_content&view=article&id=59&Itemid=41 [Accessed 2011 Oct 17]

  6. GESIDA Expert Panel and the National AIDS Plan. GESI-DA consensus document/Spanish AIDS plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection, January 2011 [online]. Available from URL: http://www.gesida.seimc.org/pcientifica/dcconsensos.asp [Accessed 2011 Feb 21]

    Google Scholar 

  7. Katlama C, Valentin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010 Sep; 24(15): 2365–74

    PubMed  CAS  Google Scholar 

  8. Ministerio de Sanidad, Política Social e Igualdad. Nomenclátor Integra Database, March 2011 [online]. Available from URL: http://www.msc.es/profesionales/farmacia/no-menclatorDI.htm [Accessed 2011 Dec 30]

    Google Scholar 

  9. Pasquau J, Hidalgo C, López Ruz MA, et al. La monoterapia basada en lopinavir o darunavir potenciados es una estrategia de simplificación segura y efectiva en los pacientes VIH+ estables. XII Congreso de la Sociedad Andaluza de Enfermedades Infecciosas, Cádiz 2010. CP-44 Avances en Enfermedades Infecciosas 2010; 11Suppl. 3: 92

    Google Scholar 

  10. Pasquau J, Hidalgo-Tenorio C, López-Ruz MA, et al. The strategy of simplification to monotherapy with boosted lopinavir or darunavir consolidates with time [abstract CP32]. 13th Congress of the Andalucian Society of Infectious Diseases; 2011 Nov 17-19; Huelva, Spain

Download references

Acknowledgements

We would like to thank the investigators and patients who participated in the 144 week MONET trial.

Conflicts of interest: AA, JG and FL are employees of Janssen, which developed the study drug darunavir. AH has received consultancy payments from Janssen. FP has no declared conflicts of interest. JP has received teaching and/or research grants from Janssen, Abbott, Bristol Myers, Merck, Viiv, Gileadd, Boeringher Ingelheim and Roche.

Author information

Authors and Affiliations

  1. Hospital Virgen de las Nieves, Granada, Spain

    Juan Pasquau

  2. Janssen, Madrid, Spain

    Joana Gostkorzewicz & Francisco Ledesma

  3. Janssen, Issy-les-Moulineaux, France

    Anne Anceau

  4. Meta Virology Ltd, London, UK

    Andrew Hill

  5. Janssen, Neuss, Germany

    Christiane Moecklinghoff

Authors
  1. Juan Pasquau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joana Gostkorzewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francisco Ledesma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anne Anceau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrew Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christiane Moecklinghoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pasquau, J., Gostkorzewicz, J., Ledesma, F. et al. Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain. Appl Health Econ Health Policy 10, 139–141 (2012). https://doi.org/10.2165/11598380-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11598380-000000000-00000

Keywords

Search

Navigation